Transplantation of umbilical cord mesenchymal stem cells alleviates pneumonitis of MRL/lpr mice

Journal of Thoracic Disease

Volumn 6, Issue 2, 2014, Pages 109-117

  Zhang, Yanju ^a   Xia, Yunfei ^a   Ni, Songshi ^a   Gu, Zhifeng ^a   Liu, Hua ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

High mobility group box protein 1 (HMGB 1); Pneumonitis; systemic lupus erythematosus (SLE); Umbilical cord mesenchymal stem cells (UC MSCs)

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS; LUNG ALVEOLUS EPITHELIUM; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEWBORN; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UMBILICAL CORD; WESTERN BLOTTING;

EID: 84896049842     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.12.48     Document Type: Article

References (50)

1. Kamen DL, Charlie S. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 2010;31:479-88.
2. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
3. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70.
4. Hayashi A, Nagafuchi H, Ito I, et al. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009;19:283-92.
5. Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974;17:331-40.
6. Owen M, Friedenstein AJ. Stromal stem cells: marrowderived osteogenic precursors. Ciba Found Symp 1988;136:42-60.
7. Prockop DJ. Marrow stromal cells as stem cells for nonhemato-poietic tissues. Science 1997;276:71-4.
8. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57:11-20.
9. Di NicolaM, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-43.
10. Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-7.
11. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
12. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389-97.
13. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
14. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
15. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-86.
16. Chen X, Armstrong MA, Li G. Mesenchymal stem cells in immunoregulation. Immunol Cell Biol 2006;84:413-21.
17. Huang K, Wu XM, Wang XY, et al. The effect of marrow mesenchymal stem cell transplantation on pulmonary fibrosis in rats. Zhonghua Jie He He Hu Xi Za Zhi 2012;35:659-64.
18. Sun LY, Zhang HY, Feng XB, et al. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007;16:121-8.
19. Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001;122:713-34.
20. Gu Z, Akiyama K, Ma XL, et al. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 2010;19:1502-14.
21. Hasegawa H, Inoue A, Muraoka M, et al. Therapy for pneumonitis and sialadenitis by accumulation of CCR2- expressing CD4+CD25+ regulatory T cells in MRL/lpr mice. Arthritis Research Therapy 2007;9:R15-27.
22. Uesugi H, Ozaki S, Sobajima J, et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol 1998;25:703-9.
23. Popovic K, Ek M, Espinosa A, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005;52:3639-45.
24. Kao AH, Sabatine JM, Manzi S. Lung disease in lupus.In: Wells AU, Denton CP. eds. Pulmonary involvement in systemic autoimmune diseases. Elsevier, 2004:125-246.
25. du Bois RM, Wells AU. The lungs and connective tissue diseases. In: Mason RJ, Broaddus VC, Murray JF, et al.eds. Textbook of respiratory medicine. Elsevier Saunders, 2005:1609-33.
26. Abu-Shakra M, Urowitz MB, Gladman DD, et al.Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
27. Brasington RD, Furst DE. Pulmonary disease in systemic lupus erythematosus. Clin Exp Rheumatol 1985;3:269-76.
28. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994;24:114-23.
29. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000;118:1083-90.
30. Chang MY, Fang JT, Chen YC, et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus: a single center retrospective study in Taiwan. Ren Fail 2002;24:791-802.
31. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: longterm follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4.
32. Nellessen CM, Poge U, Brensing KA, et al. Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: a case report. Nephrol Dial Transplant 2008;23:385-6.
33. Pinto LF, Candia L, Garcia P, et al. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti- CD20 antibody (rituximab). Respiration 2009;78:106-9.
34. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33:145-52.
35. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.PNAS 2003;100:8407-11.
36. Zhao F, Li SQ, Zhang YF, et al. Differentiation of bone marrow mesenchymal stem cells in injured rat lung. Medical Journal of Chinese People's Liberation Army 2007;32:131-3.
37. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36-42.
38. Rovere-Querini P, Capobianco A, Scaffidi P, et al.HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004;5:825-30.
39. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001.
40. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70.
41. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
42. Park JS, Svetkauskaite D, He Q, et al. Involvement of Tolllike receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7.
43. Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003;284:C870-9.
44. Lenz O, Contreras G. Treatment options for severe lupus nephritis. Arch Immunol Ther Exp (Warsz) 2004;52:356-65.
45. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
46. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-924.
47. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
48. Deocharan B, Zhou Z, Antar K, et al. Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice. J Immunol 2007;179:1313-21.
49. Al-Mutairi S, Al-Awadhi A, Raghupathy R, et al.Lupus patients with pulmonary involvement have a proinflammatory cytokines profile. Rheumatology Int 2007;7:621-30.
50. Entezari M, Weiss DJ, Sitapara R, et al. Inhibition of highmobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18:477-85.